drugset / Trial / NCT07116824
HB1801 Combined Treatment of HER2-positive Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety and efficacy of HB1801 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic breast cancer.
Timeline
- Start
- 2025-09-15
- Primary completion
- 2026-07-15
- Completion
- 2027-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | HB1801 | Unknown | — | Intravenous |
| Background | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |